Asia 1、O型口蹄疫病毒多表位疫苗的研究
|
摘要
口蹄疫是由口蹄疫病毒引起偶蹄兽猪、牛、羊等主要经济畜种发病的重大动物疫病。FMDV灭活疫苗作为FMD综合防控体系的重要组成部分,为有效防控和净化口蹄疫做出了十分重要的贡献,但灭活疫苗也存在诸多的缺点和不足,如需要区分疫苗免疫动物和自然感染动物,需要建设生物安全实验室;最为严重的是,病毒有逃逸生产车间的危险。分子生物学技术的发展以及合成肽免疫原性的证实,为研制FMDV抗原表位疫苗提供了理论依据和技术支持,人们对FMDV抗原表位疫苗进行了广泛的研究,在小动物模型显示出了良好的免疫效力,但是对本动物的免疫效果并不理想。近年来我国口蹄疫疫情有所抬头,出现A,O,Asia 1多个血清型交替流行的态势,严重地威胁我国畜牧业的健康发展,为了有效控制和净化在我国流行的FMDV,本研究针对我国目前流行的Asia 1型和O型FMDV毒株,利用分子生物学,蛋白质工程及其相关技术进行羊口蹄疫病毒Asia 1多表位疫苗和猪口蹄疫病毒O型多表位疫苗的研究,为我国有效防控FMD提供优质安全的疫苗储备。
针对目前流行的Asia 1型江苏毒株,设计并合成了病毒主要抗原VP1的135-160肽段和197-211肽段的重复串联表位基因(RE)。采用RT-PCR技术克隆了羊的免疫球蛋白重链恒定区基因(OIgGC)和Asia 1病毒的3D基因,将3D、RE、OIgGC分别或融合插入pET-30a构建了一系列重组表达质粒pRE-OIgGC,p3D,pOIgGC,将RE插入pGEX-4T-1构建了pGST-RE重组表达质粒,并实现了这些重组蛋白在E.coli的规模化表达及高通量纯化,所有重组蛋白以包涵体形式表达。Western blotting结果显示,重组蛋白RE-OIgGC,3D和GST-RE能与FMDV阳性血清发生免疫反应,OIgGC能与兔抗羊血清发生免疫反应。将适量的重组抗原与等体积的ISA206佐剂混合制备一系列疫苗,即OIgGC(100μg/ml),RE-OIgGC(100μg/ml),RE-OIgGC(100μg/ml)+3D(50μg/ml)和GST-RE(100μg/ml)。通过免疫豚鼠和羊体,测定血清中和抗体效价、淋巴细胞增殖实验和攻毒保护实验对候选疫苗进行免疫效力评价。免疫豚鼠结果显示,除了PBS和OIgGC组外,重组蛋白RE-OIgGC,RE-OIgGC+3D和GST-RE均能诱导产生保护性中和抗体,加强免疫后能保护动物抵抗103 ID50口蹄疫病毒的攻击。添加FMD病毒3D的多表位疫苗组的中和抗体水平最高,与灭活疫苗诱导的中和抗体效价没有明显的不同。以GST和为载体蛋白的重组抗原免疫豚鼠后血清中和抗体并没有明显差异。另外,添加3D蛋白的疫苗组诱导了最高水平的淋巴细胞增殖,充分说明了3D蛋白具有改善体液免疫反应和诱发T细胞免疫反应的能力。羊免疫结果显示,以宿主自身分子IgG重链恒定区为载体蛋白的2组多表位疫苗的中和抗体水平明显高于以GST分子为载体蛋白组,加强免疫后血清中和抗体效价明显快速升高,说明OIgGC发挥了生物学功能,明显改善了多表位抗原的免疫原性,而3D蛋白的免疫佐剂功能不是特别明显。
设计并合成了FMD病毒O型主要抗原VP1的140-160肽段和200-213肽段的重复串联表位基因(RE)。利用RT-PCR扩增了猪的免疫球蛋白重链恒定区基因(SIgGC)和O型病毒的3D基因,将3D、RE、SIgGC分别或融合插入pET-22b成功构建了重组表达质粒pRE-SIgGC和p3D,并实现了RE-SIgGC和3D重组蛋白在E.coli的规模化表达及高通量纯化,以包涵体形式表达的重组蛋白经Western blotting证实具有免疫反应性。RE-SIgGC和3D重组蛋白经纯化后按照适当比例进行混合,并与与氢氧化铝、完全弗氏佐剂和ISA206等多种佐剂配伍成10种不同形式的猪口蹄疫病毒O型多表位疫苗,通过本动物猪免疫效力试验筛获了一种候选疫苗,单剂免疫猪体后免疫效力达到甚至优于传统灭活疫苗。随后用试制的三批疫苗进行了候选疫苗的最小免疫剂量、免疫效力(PD50)、保存期和免疫持续期以及抗体消长情况测定,全面评价疫苗的免疫效力。结果显示,用抗原含量为83μg的疫苗免疫猪,不仅能诱发机体产生高滴度的保护性中和抗体,而且能保护猪只抵抗103 ID50口蹄疫病毒感染,5/5保护;三批候选疫苗的PD50为5.20~10.05达到甚至高于国家标准(3.0 PD50);免疫动物后30天,血清中和抗体达到峰值,此后,随时间的延长中和抗体效价开始下降,免疫后7个月内血清中和抗体水平仍然维持在较高水平,大多数(70%)免疫动物能够抵抗病毒的感染;疫苗于2~8℃保存12个月并不影响疫苗的免疫效力。这些结果充分说明了本研究研制的猪口蹄疫病毒O型多表位疫苗是一种具有良好开发前景的疫苗,有望替代灭活疫苗用于我国口蹄疫病毒的防控。
总之,通过本研究我们成功设计、构建了Asia 1和O型口蹄疫病毒的多表位疫苗的组装体系和表达体系,并实现了重组抗原的规模化原核表达和高通量纯化。通过引入具有重要免疫学功能的宿主自身分子IgG和具有佐剂功能的FMDV的3D蛋白,明显提高了多表位疫苗的免疫效力,并诱发了T细胞免疫反应。通过豚鼠和本动物羊和猪筛获了具有良好免疫效力的候选疫苗,尤其是筛获的猪口蹄疫病毒O型多表位候选疫苗不仅具有良好免疫效力,而且抗原用量少、免疫持续期长,疫苗在2~8℃保存稳定,是一种十分具有开发前景的疫苗,对其他动物病毒抗原表位疫苗的研制具有借鉴意义。
Foot-and-mouth (FMD) is a highly contagious and economically devastating viral disease of cloven-hoofed live-stock including pig, cattle, sheep and goats that causing by foot-and-mouth disease virus (FMDV). The inactivated FMDV vaccines as one of the systematic implements of prevention and control disease play a crucial role for control and eradication of FMD. However, the inactivated vaccines have several disadvantages including difficulty to discriminate between infected and vaccinated animals, requiring of the safe building biologically. Seriously, there is a potential risk of live virus escaping from vaccine plants. Development of the molecular biology and validation of immunogenicity of the synthetic peptides offer the theories and techniques for development of antigenic epitope vaccines to FMDV. To date, there were a lots of reports about antigenic epitope vaccines to FMDV and their immune potential is promising in the small model. However, they confer the limited immune responses in the natural hosts. In recent years, outbreaks of FMD frequently occur in China, particularly, several FMDV serotypes including types Asia 1, O and A alternately occurred, which the severely impact to the live-stock and animal’s products in China. With a aim to control and eradicate FMDV occurred in China, the multiple-epitope vaccines to FMDV type Asia 1 in sheep and FMDV type O in swine have been developed with the molecular biology, proteins engineering and relative techniques, based on the current prevalent FMDV isolates type O and Asia 1. These vaccines as a safe and efficacy alternative will redound to prevention and control of FMD in China in the future.
We designed and synthesized a tandem-repeated multiple-epitopes gene (RE) based on residues 135-160 and 197-211 of FMDV VP1 type Asia 1 Jiangsu isolate occurred in China. The ovine immunoglubine G heavy constant region gene (OIgGC) and 3D of FMDV type Asia 1 were amplified by RT-PCR. A series of the recombinant expression plasmids, pRE-OIgGC, p3D and pOIgGC, were constructed by directly inserting RE-OIgGC, 3D and OIgGC into an expression vector, pET-30a, respectively. The RE was purified and subcloned into an expression vector, pGEX-4T-1, which resulted in a recombinant plasmid, pGST-RE. These recombinant proteins were large-scale expressed in E.coli and the high-throughput purification proteins were obtained. All of the recombinant proteins were expressed as a formation of inclusion bodies in E.coli. Western blotting results showed that the recombinant RE-OIgGC, 3D and GST-RE are able to react with anti-FMDV positive serum, and the OIgGC is able to recognized by rabit anti-goat IgG. A series of vaccines, OIgGC(100μg/ml),RE-OIgGC(100μg/ml),RE-OIgGC(100μg/ml)+3D(50μg/ml) and GST-RE(100μg/ml)were performed by emulsification of appropriate proteins with a equal volume of ISA206. Potency of immunity of vaccine candidates in guinea pigs and sheep was evaluated by detection of neutralizing antibodies in serum, lymphocytes proliferation assay and virus challenge test. The results of the vaccinated guinea pigs showed that the recombinant proteins, RE-OIgGC, RE-OIgGC+3D and GST-RE, except groups PBS and OIgGC are able to elicit protective levels of neutralizing antibodies in the vaccinated guinea pigs and to offer compelete protection of guinea pigs against 103 ID50 of virus challenge. The multiple-epitope vaccine containing 3D is able to induce the highest titers of neutralizing antibodies than that of other proteins, which is the same high as that of the inactivated vaccine. Regretingly, the GST-RE elicit the same high levels of neutralizing antibodies as that of the RE-OIgGC. The possible explanation for this phenomenon is that the carrier proteins, GST and OIgGC, are the foreign proteins to the guinea pigs. In addition, the vaccine containing 3D is also able to the highest levels of lymphocytes proliferation than that of other vaccine candidates. These results demonstrated that 3D protein is not only able to improve the humoral immune responses, but to elicit T cell immune responses. The results of the vaccinated sheep showed that two groups, RE-OIgGC and RE-OIgGC+3D, elicit the significant higher level of neutralizing antibodies than that of GST-RE. The neutralizing antibodies is signifcantly rapid raise after booster vaccination compared with the initiation vaccination, which demonstrated that OIgGC play an important function biologically and significantly enhance the immunogenicity of the multiple-epitope vaccine. However, the immune adjuvant function of 3D protein was not especially distinctness in the vaccinated sheep.
A tandem-repeated multiple-epitope gene (RE) containing residues 140-160 and 197-211 of VP1 of FMDV type O was designed and synthesized. A swine immunoglubine G heavy constant region (SIgGC) and 3D of FMDV type O were amplified by RT-PCR. The gene 3D, RE and SIgGC were subcloned into a expression vector, pET-22b, which resulted in the recombinant expression plasmids, pRE-SIgGC and p3D. The recombinant proteins, RE-SIgGC and 3D, were large-scale expressed in E.coli and highly throughput purified. The recombinant proteins were expressed as a formation of inclusion bodies in E.coli, and their immunoreactivity was verified with Western blotting. The RE-SIgGC and 3D was purified with Ni-NTA resin and a mixture of RE-SIgGC and 3D was developed according to an appropriate concentration ratio of two proteins. Subsequently, ten different multiple-epitopes vaccines to FMDV type O in swine were developed by emulsification of the mixture of proteins with a equal volume of several adjuvants including Al(OH)3, compelete Freund’s adjuvant and ISA206 etc. Potency of immunity of ten vaccines were evaluated by vaccinated swine, and then a vaccine candidate has been screened. The results showed that the potency of immunity in swine vaccinated with single-dose vaccination is the same or higher than that of the traditionally inactivated vaccine. Three sets of vaccine candidates have been developed in our laboratory and their potency of immunity were systematically evaluated including detection of the minimum immune dosage, potency of immunity (PD50), duration of storage, duration of immunity and variation of neutralizing antobides after vaccination. The results showed that a vaccine candidate containing 83μg mixture of antigen is able to elicite the higher titers of neutralizing antibodies and to offer compelete protection of swine agaisnt 103 ID50 of virus challenge, protective ratio is 5/5. Potency of immunity from three sets of vaccine candidates are about 5.20-10.05 PD50 that is higher than the country standard (3.0 PD50). The titers of neutralizing antibodies reach the peak at days 30 post-vaccination, and the titers of neutralizing antibodies are gradually decline over times. Inspiringly, at months 7 post-vaccination, the higher titers of neutralizing antibodies were remained and majority of the vaccinated swine (70%) were compelete protection against virus challenge. Potency of immunity is not affected when vaccine candidate stored at 2-8℃for 12 months. These results indicated that we have developed multiple-epitope vaccine to FMDV type O in swine is a promising vaccine candidate, which may be to replace the traditionally inactivated and to be use for the control and prevention of FMD in China in the future.
Conclusions, we have successfully designed and constructed the systems of assembly and expression for the multiple-epitopes vaccines to FMDV type O and Asia 1. The recombinant proteins were large-scale expressed in E.coli and highly throughput purified proteins were obtained. An immunological important molecular, host self immunoglubine G, and 3D of FMDV as a adjuvant were considerated in the designing of multiple-epitopes vaccine, which significantly improve the potency of immunity of vaccine and elicite cell immune responses. The higher potency vaccine candidates were selected by vaccination of guinea pigs, sheep and pigs. Particularly, the selected multiple-epitope vaccine candidate to FMDV type O in swine has several advantages including a higher potency of immunity, lower amount of antigen, longer duration of immunity and good stability stored at 2-8℃. Therefore, we have developed vaccine candidate is a promising vaccine, which will be used for the reference to develep multiple-epitope vaccines to other animal’s viruses.
针对目前流行的Asia 1型江苏毒株,设计并合成了病毒主要抗原VP1的135-160肽段和197-211肽段的重复串联表位基因(RE)。采用RT-PCR技术克隆了羊的免疫球蛋白重链恒定区基因(OIgGC)和Asia 1病毒的3D基因,将3D、RE、OIgGC分别或融合插入pET-30a构建了一系列重组表达质粒pRE-OIgGC,p3D,pOIgGC,将RE插入pGEX-4T-1构建了pGST-RE重组表达质粒,并实现了这些重组蛋白在E.coli的规模化表达及高通量纯化,所有重组蛋白以包涵体形式表达。Western blotting结果显示,重组蛋白RE-OIgGC,3D和GST-RE能与FMDV阳性血清发生免疫反应,OIgGC能与兔抗羊血清发生免疫反应。将适量的重组抗原与等体积的ISA206佐剂混合制备一系列疫苗,即OIgGC(100μg/ml),RE-OIgGC(100μg/ml),RE-OIgGC(100μg/ml)+3D(50μg/ml)和GST-RE(100μg/ml)。通过免疫豚鼠和羊体,测定血清中和抗体效价、淋巴细胞增殖实验和攻毒保护实验对候选疫苗进行免疫效力评价。免疫豚鼠结果显示,除了PBS和OIgGC组外,重组蛋白RE-OIgGC,RE-OIgGC+3D和GST-RE均能诱导产生保护性中和抗体,加强免疫后能保护动物抵抗103 ID50口蹄疫病毒的攻击。添加FMD病毒3D的多表位疫苗组的中和抗体水平最高,与灭活疫苗诱导的中和抗体效价没有明显的不同。以GST和为载体蛋白的重组抗原免疫豚鼠后血清中和抗体并没有明显差异。另外,添加3D蛋白的疫苗组诱导了最高水平的淋巴细胞增殖,充分说明了3D蛋白具有改善体液免疫反应和诱发T细胞免疫反应的能力。羊免疫结果显示,以宿主自身分子IgG重链恒定区为载体蛋白的2组多表位疫苗的中和抗体水平明显高于以GST分子为载体蛋白组,加强免疫后血清中和抗体效价明显快速升高,说明OIgGC发挥了生物学功能,明显改善了多表位抗原的免疫原性,而3D蛋白的免疫佐剂功能不是特别明显。
设计并合成了FMD病毒O型主要抗原VP1的140-160肽段和200-213肽段的重复串联表位基因(RE)。利用RT-PCR扩增了猪的免疫球蛋白重链恒定区基因(SIgGC)和O型病毒的3D基因,将3D、RE、SIgGC分别或融合插入pET-22b成功构建了重组表达质粒pRE-SIgGC和p3D,并实现了RE-SIgGC和3D重组蛋白在E.coli的规模化表达及高通量纯化,以包涵体形式表达的重组蛋白经Western blotting证实具有免疫反应性。RE-SIgGC和3D重组蛋白经纯化后按照适当比例进行混合,并与与氢氧化铝、完全弗氏佐剂和ISA206等多种佐剂配伍成10种不同形式的猪口蹄疫病毒O型多表位疫苗,通过本动物猪免疫效力试验筛获了一种候选疫苗,单剂免疫猪体后免疫效力达到甚至优于传统灭活疫苗。随后用试制的三批疫苗进行了候选疫苗的最小免疫剂量、免疫效力(PD50)、保存期和免疫持续期以及抗体消长情况测定,全面评价疫苗的免疫效力。结果显示,用抗原含量为83μg的疫苗免疫猪,不仅能诱发机体产生高滴度的保护性中和抗体,而且能保护猪只抵抗103 ID50口蹄疫病毒感染,5/5保护;三批候选疫苗的PD50为5.20~10.05达到甚至高于国家标准(3.0 PD50);免疫动物后30天,血清中和抗体达到峰值,此后,随时间的延长中和抗体效价开始下降,免疫后7个月内血清中和抗体水平仍然维持在较高水平,大多数(70%)免疫动物能够抵抗病毒的感染;疫苗于2~8℃保存12个月并不影响疫苗的免疫效力。这些结果充分说明了本研究研制的猪口蹄疫病毒O型多表位疫苗是一种具有良好开发前景的疫苗,有望替代灭活疫苗用于我国口蹄疫病毒的防控。
总之,通过本研究我们成功设计、构建了Asia 1和O型口蹄疫病毒的多表位疫苗的组装体系和表达体系,并实现了重组抗原的规模化原核表达和高通量纯化。通过引入具有重要免疫学功能的宿主自身分子IgG和具有佐剂功能的FMDV的3D蛋白,明显提高了多表位疫苗的免疫效力,并诱发了T细胞免疫反应。通过豚鼠和本动物羊和猪筛获了具有良好免疫效力的候选疫苗,尤其是筛获的猪口蹄疫病毒O型多表位候选疫苗不仅具有良好免疫效力,而且抗原用量少、免疫持续期长,疫苗在2~8℃保存稳定,是一种十分具有开发前景的疫苗,对其他动物病毒抗原表位疫苗的研制具有借鉴意义。
Foot-and-mouth (FMD) is a highly contagious and economically devastating viral disease of cloven-hoofed live-stock including pig, cattle, sheep and goats that causing by foot-and-mouth disease virus (FMDV). The inactivated FMDV vaccines as one of the systematic implements of prevention and control disease play a crucial role for control and eradication of FMD. However, the inactivated vaccines have several disadvantages including difficulty to discriminate between infected and vaccinated animals, requiring of the safe building biologically. Seriously, there is a potential risk of live virus escaping from vaccine plants. Development of the molecular biology and validation of immunogenicity of the synthetic peptides offer the theories and techniques for development of antigenic epitope vaccines to FMDV. To date, there were a lots of reports about antigenic epitope vaccines to FMDV and their immune potential is promising in the small model. However, they confer the limited immune responses in the natural hosts. In recent years, outbreaks of FMD frequently occur in China, particularly, several FMDV serotypes including types Asia 1, O and A alternately occurred, which the severely impact to the live-stock and animal’s products in China. With a aim to control and eradicate FMDV occurred in China, the multiple-epitope vaccines to FMDV type Asia 1 in sheep and FMDV type O in swine have been developed with the molecular biology, proteins engineering and relative techniques, based on the current prevalent FMDV isolates type O and Asia 1. These vaccines as a safe and efficacy alternative will redound to prevention and control of FMD in China in the future.
We designed and synthesized a tandem-repeated multiple-epitopes gene (RE) based on residues 135-160 and 197-211 of FMDV VP1 type Asia 1 Jiangsu isolate occurred in China. The ovine immunoglubine G heavy constant region gene (OIgGC) and 3D of FMDV type Asia 1 were amplified by RT-PCR. A series of the recombinant expression plasmids, pRE-OIgGC, p3D and pOIgGC, were constructed by directly inserting RE-OIgGC, 3D and OIgGC into an expression vector, pET-30a, respectively. The RE was purified and subcloned into an expression vector, pGEX-4T-1, which resulted in a recombinant plasmid, pGST-RE. These recombinant proteins were large-scale expressed in E.coli and the high-throughput purification proteins were obtained. All of the recombinant proteins were expressed as a formation of inclusion bodies in E.coli. Western blotting results showed that the recombinant RE-OIgGC, 3D and GST-RE are able to react with anti-FMDV positive serum, and the OIgGC is able to recognized by rabit anti-goat IgG. A series of vaccines, OIgGC(100μg/ml),RE-OIgGC(100μg/ml),RE-OIgGC(100μg/ml)+3D(50μg/ml) and GST-RE(100μg/ml)were performed by emulsification of appropriate proteins with a equal volume of ISA206. Potency of immunity of vaccine candidates in guinea pigs and sheep was evaluated by detection of neutralizing antibodies in serum, lymphocytes proliferation assay and virus challenge test. The results of the vaccinated guinea pigs showed that the recombinant proteins, RE-OIgGC, RE-OIgGC+3D and GST-RE, except groups PBS and OIgGC are able to elicit protective levels of neutralizing antibodies in the vaccinated guinea pigs and to offer compelete protection of guinea pigs against 103 ID50 of virus challenge. The multiple-epitope vaccine containing 3D is able to induce the highest titers of neutralizing antibodies than that of other proteins, which is the same high as that of the inactivated vaccine. Regretingly, the GST-RE elicit the same high levels of neutralizing antibodies as that of the RE-OIgGC. The possible explanation for this phenomenon is that the carrier proteins, GST and OIgGC, are the foreign proteins to the guinea pigs. In addition, the vaccine containing 3D is also able to the highest levels of lymphocytes proliferation than that of other vaccine candidates. These results demonstrated that 3D protein is not only able to improve the humoral immune responses, but to elicit T cell immune responses. The results of the vaccinated sheep showed that two groups, RE-OIgGC and RE-OIgGC+3D, elicit the significant higher level of neutralizing antibodies than that of GST-RE. The neutralizing antibodies is signifcantly rapid raise after booster vaccination compared with the initiation vaccination, which demonstrated that OIgGC play an important function biologically and significantly enhance the immunogenicity of the multiple-epitope vaccine. However, the immune adjuvant function of 3D protein was not especially distinctness in the vaccinated sheep.
A tandem-repeated multiple-epitope gene (RE) containing residues 140-160 and 197-211 of VP1 of FMDV type O was designed and synthesized. A swine immunoglubine G heavy constant region (SIgGC) and 3D of FMDV type O were amplified by RT-PCR. The gene 3D, RE and SIgGC were subcloned into a expression vector, pET-22b, which resulted in the recombinant expression plasmids, pRE-SIgGC and p3D. The recombinant proteins, RE-SIgGC and 3D, were large-scale expressed in E.coli and highly throughput purified. The recombinant proteins were expressed as a formation of inclusion bodies in E.coli, and their immunoreactivity was verified with Western blotting. The RE-SIgGC and 3D was purified with Ni-NTA resin and a mixture of RE-SIgGC and 3D was developed according to an appropriate concentration ratio of two proteins. Subsequently, ten different multiple-epitopes vaccines to FMDV type O in swine were developed by emulsification of the mixture of proteins with a equal volume of several adjuvants including Al(OH)3, compelete Freund’s adjuvant and ISA206 etc. Potency of immunity of ten vaccines were evaluated by vaccinated swine, and then a vaccine candidate has been screened. The results showed that the potency of immunity in swine vaccinated with single-dose vaccination is the same or higher than that of the traditionally inactivated vaccine. Three sets of vaccine candidates have been developed in our laboratory and their potency of immunity were systematically evaluated including detection of the minimum immune dosage, potency of immunity (PD50), duration of storage, duration of immunity and variation of neutralizing antobides after vaccination. The results showed that a vaccine candidate containing 83μg mixture of antigen is able to elicite the higher titers of neutralizing antibodies and to offer compelete protection of swine agaisnt 103 ID50 of virus challenge, protective ratio is 5/5. Potency of immunity from three sets of vaccine candidates are about 5.20-10.05 PD50 that is higher than the country standard (3.0 PD50). The titers of neutralizing antibodies reach the peak at days 30 post-vaccination, and the titers of neutralizing antibodies are gradually decline over times. Inspiringly, at months 7 post-vaccination, the higher titers of neutralizing antibodies were remained and majority of the vaccinated swine (70%) were compelete protection against virus challenge. Potency of immunity is not affected when vaccine candidate stored at 2-8℃for 12 months. These results indicated that we have developed multiple-epitope vaccine to FMDV type O in swine is a promising vaccine candidate, which may be to replace the traditionally inactivated and to be use for the control and prevention of FMD in China in the future.
Conclusions, we have successfully designed and constructed the systems of assembly and expression for the multiple-epitopes vaccines to FMDV type O and Asia 1. The recombinant proteins were large-scale expressed in E.coli and highly throughput purified proteins were obtained. An immunological important molecular, host self immunoglubine G, and 3D of FMDV as a adjuvant were considerated in the designing of multiple-epitopes vaccine, which significantly improve the potency of immunity of vaccine and elicite cell immune responses. The higher potency vaccine candidates were selected by vaccination of guinea pigs, sheep and pigs. Particularly, the selected multiple-epitope vaccine candidate to FMDV type O in swine has several advantages including a higher potency of immunity, lower amount of antigen, longer duration of immunity and good stability stored at 2-8℃. Therefore, we have developed vaccine candidate is a promising vaccine, which will be used for the reference to develep multiple-epitope vaccines to other animal’s viruses.
引文
1.谢庆阁.口蹄疫[M].中国农业出版社, 2004.
2. Thomson GR, Vosloo W, Bastos AD. Foot and mouth disease in wildlife[J]. Virus Res, 2003, 91: 65-80.
3. Grubman MJ, Baxt B. Foot-and-mouth disease[J]. Clin Microbiol Rev, 2004, 17(2): 465-493.
4. Yang PC, Chu RM, Chung WB, et al. Epidemiological characteristics and financial costs of the 1997 foot-and-mouth disease epidemic in Taiwan [J]. Vet Rec, 1999, 145(25): 731-734.
5. Haydon DT, Kao RR, Kitching RP. The UK foot-and-mouth disease outbreak—the aftermath[J]. Nature review: microbiology, 2004, 2:674-681.
6. Barnett PV, Pullen L, Williams L, et al. 1996. International bank for foot-and-mouth disease vaccine: assessment of Montanide ISA 25 and ISA 206, two commercially available oil adjuvants[J]. Vaccine, 14: 1187–1198.
7. Barteling SJ, Vreeswijk J. Developments in foot-and-mouth disease[J]. Vaccine, 1991, 9: 75-88.
8. Doel TR. FMD vaccines[J]. Virus Res, 2003, 91(1): 81-99.
9. Lu Z Cao Y, Guo J, et al. Development and validation of a 3ABC indirect ELISA for differentiation of foot-and-mouth disease virus infected from vaccinated animals[J]. Vet Microbiol, 2007, 125: 157-169.
10. Mackay DK, Forsyth MA, Davies PR, et al. Differentiating infection from vaccination in foot-and-mouth disease using a panel of recombinant, non-structural proteins in ELISA[J]. Vaccine, 1998, 16: 446-459.
11. Sutmoller P, Casas Olascoaga R. The risks posed by the importation of animals vaccinated against foot and mouth disease and products derived from vaccinated animals: a review[J]. Rev Sci Tech, 2003, 22: 823-835
12. Beck E, and Strohmaier K. Subtyping of European foot-and-mouth disease virusstrains by nucleotide sequence determination[J]. J Virol, 1987, 61: 1621-1629.
13. Brown F. New approaches to vaccination against foot-and-mouth disease[J]. Vaccine, 1992, 10: 1022-1026.
14. King AM, Underwood BO, McCahon D, et al. Biochemical identification of viruses causing the 1981 outbreaks of foot and mouth disease in the UK[J]. Nature, 1981, 293: 479-480.
15. Wu Q, Moraes MP, Grubman M J. Recombinant adenovirus co-expressing capsid proteins of two serotypes of foot-and-mouth disease virus (FMDV): in vitro characterization and induction of neutralizing antibodies against FMDV in swine [J]. Virus Res, 2003, 93: 211-219.
16. Yi JZ, Liu MQ, Zhu CZ, et al. Recombinant bivalent vaccine against Foot-and-Mouth Disease Virus Serotype O/A infection in guinea pig[J]. Acta. Biochemica et Biophysica Sinica, 2004, 36: 589-596.
17. He YN, Qian P, Zhang KS, et al. Construction and immune response characterization of a recombinant pseudorabies virus co-expressing capsid precursor protein (P1) and a multiepitope peptide of foot-and-mouth diesase virus in swine[J]. Virus Genes, 2008, 36: 393-400.
18. Sanz-Parra A, Vázquez B, Sobrino F, et al. Evidence of partial protection against foot-and-mouth disease in cattle immunized with a recombinant adenovirus vector expressing the precursor polypeptide (P1) of foot-and-mouth disease virus capsid proteins[J]. J Gen Virol, 1999, 80: 671-679.
19. Sanz-Parra A, Jimenez-Clavero MA, García-Briones MM, et al. Recombinant viruses expressing the foot-and-mouth disease virus capsid precursor polypeptide (P1) induce cellular but not humoral antiviral immunity and partial protection in pigs[J]. Virology, 1999, 259: 129-134.
20. Lu Z, Bao H, Cao Y, et al. Protection of guinea pigs and swine by a recombinant adenovirus expressing O serotype of foot-and-mouth disease virus whole capsid and 3C protease[J]. Vaccine, 2008, 26S: G48–G53.
21. Bittle JL, Houghten RA, Alexander H, et al. Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted fromthe viral nucleotide sequence[J]. Nature, 1982, 298: 30-33.
22. Doel TR, Gale C, Do Amaral CM, et al. Heterotypic protection induced by synthetic peptides corresponding to three serotypes of foot-and-mouth disease virus[J]. J Virol, 1990, 64:2260-2264.
23. Meloen RH, Casal JI, Dalsgaard K, et al. Synthetic peptide vaccine: success at last[J]. Vaccine, 1995, 13: 127-133.
24. Morgan DO, Moore DM. Protection of cattle and swine against foot-and-mouth disease, using biosynthetic peptide vaccines[J]. Am J Vet Res, 1990, 51: 40-45.
25. Rodriguez LL, Barrera J, Kramer E, et al. A synthetic peptide containing the consensus sequence of the G-H loop region of foot-and-mouth disease virus type O VP1 and a promiscuous T-helper epitope induces eptide-specific antibodies but fails to protect cattle against viral challenge. Vaccine. 2003. 21: 3751-3756.
26. Su CX, Duan XG, Wang XQ, et al. Heterologous of FMDV immunodominant epitopes and HSP70 in P.pastoris and the subesequent immune response in mice[J]. Vet Mirobiol, 2007, 124: 256-263.
27. Winther MD, Allen G, Bomford RH, et al. Bacterially expressed antigenic peptide from foot-and-mouth disease virus capsid elicits variable immunologic responses in animals[J]. J Immunol, 1986, 136: 1835-1840.
28. Borrego B, Fernandez-Pacheco P, Ganges L, et al. Fernandez-Borges, F. Sobrino, and F. Rodríguez. DNA vaccines expressing B and T cell epitopes can protect mice from FMDV infection in the absence of specific humoral responses[J]. Vaccine. 2006, 24: 3889-3899.
29. Guo H, Sun S, Ma J, et al. A Bicistronic DNA Vaccine Containing Gene of FMDV and Bovine IFN-αCan Prime Humoral and Cellular Immune Responses of Guinea Pigs[J]. Turk J Vet Anim Sci, 2008, 32(2): 85-91.
30. Li Y, Stirling CMA, Michael S. Dramatic improvement in FMD DNA vaccine efficacy and cross-serotype antibody induction in pigs following a protein boost [J]. Vaccine, 2008, 26: 2647-2656.
31. Li Y, Aggarwal N, Takamatsu HH, et al. Enhancing immune responses against a plasmi DNA vaccine encoding a FMDV empty capsid from serotype O[J].Vaccine, 2006, 24: 4602-4606.
32. Yang B, Lan X, Li X, et al. A novel bi-functional DNA vaccine expressing VP1 protein and producing antisense RNA targeted to 5′UTR of foot-and-mouth disease virus can induce both rapid inhibitory effect and specific immune response in mice[J]. Vaccine, 2008, 26: 5477-5483.
33. Sutmoller P, Barteling SJ. The history of foot-and-mouth disease vaccine development: a personal perspective. In: foot-and-mouth disease: Control Strategies[M]. Dondet, B and Vicari, M. eds. Elsevier Amsterdam and New York. 337-343.
34. Sutmoller P, Barteling SS, Olascoaga RC, et al. Control and eradication of foot-and-mouth disease[J]. Virus Res, 2003, 91(1): 101-144.
35. Sa-Carvalho D, Rieder E, Baxt B, et al. Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle[J]. J Virol, 1997, 71: 5115–5123.
36. McKenna TS, Lubroth J, Rieder E, et al. Receptor binding site-deleted foot-and-mouth disease (FMD) virus protects cattle from FMD[J]. J Virol, 1995, 69: 5787–5790.
37. Brown CC, Piccone ME, Mason PW, et al. Pathogenesis of wild-type and leaderless foot-and-mouth disease virus in cattle[J]. J Virol, 1996, 70(8): 5638–5641.
38. Chinsangaram J, Mason PW, Grubman MJ. Protection of swine by live and inactivated vaccines prepared froma leader proteinase-deficient serotype A12 foot-and-mouth disease virus. Vaccine 1998;16(16):1516–1522.
39. Mason PW, Piccone ME, McKenna TS, et al. Evaluation of a live-attenuated foot-and-mouth disease virus as a vaccine candidate.Virology, 1997, 227(1): 96–102.
40. Almeida MR, Rieder E, Chinsangaram J, et al. Construction and evaluation of an attenuated vaccine for foot-and-mouth disease: difficulty adapting the leader proteinase-deleted strategy to the serotype O1 virus[J]. Virus Res, 1998, 55: 49–60.
41. Rodríguez Pulido M, Sobrino Francisco, Borrego B, et al. Attenuated Foot-and-Mouth Disease Virus RNA Carrying a Deletion in the 3′Noncoding Region Can Elicit Immunity in Swine[J]. J Virol, 2009, 38: 3475–3485.
42. Vallee H, Carre H, Rinjard P. On immunization agaisnt foot-and-mouth diesease [J]. Rech Med Vet, 1925, 101: 297-299.
43. Waldmann O, K?be K, Pyl G. Die aktive Immunisierung des Rindes gegen Maul-und Klauenseuche mittels Formolimpfstoff[J]. Zent Bakt Parasi Infekt, 1937, 138: 401-412.
44. Frenkel HS. La culture du virus de la fiévre aphteuse surl’épithélium de la langue des bovidés[J]. Bull, Off, Int, Epiz, 1947, 28: 155-162.
45. Francisico Sobrino, Esteban Domingo. Foot-and-mouth disease current perspectives[M]. British, 2004.
46. Ubertini B, Nardelli L, Dal Panina A, et al. BHK-21cell cultures for the large scale production of foot-and-mouth disease[J]. Zbl Vet Med B, 14: 432.
47. Capstick PB, Telling RC, Chapman WG, et al. Growth of a cloned strain of hamster kidney cells in suspended cultures and their susceptibility to the virus of foot-and-mouth disease[J]. Nature, 1962, 195: 1163-1164.
48. Telling RC, Elsworth R. Submerged culture of hamster kidney cells in a stainless steel vessel[J]. Biotechnol Bioeng, 1965, 7: 417-434.
49. Correa Melo E, Saraiva V, Astudillo V. Review of the status of foot and mouth disease in countries of South America and approaches to control and eradication[J]. Rev Sci Tech Off Int Epizoot, 2002, 21: 429–436.
50. Doel TR, Pullen L. International bank for foot-and-mouth disease vaccine: stability studies with virus concentrates and vaccines prepared from them[J]. Vaccine, 1990, 8: 473-478.
51. Brown F, Crick, Joan. Application of agar-gel diffusion analysis to a study of the antigenic structure of inactivated vaccines prepared from the virus of foot and mouth disease[J]. J Immunol, 1959, 82: 444-447.
52. Bahnemann HG. The inactivation of foot and mouth disease virus by ethyleneimine and propyleneimine[J]. Zbl Vet Med B, 1973, 20: 356-360.
53. Freund J. The mode of action of immunologic adjuvants[J]. Adv Tuberc Res, 1956, 7: 130-148.
54. Michelsen E. Experiences on vaccination of pigs[J]. Arch Exp Vet Med, 1961, 15: 317-321.
55. Cunliffe HR, Graves JH. Formalin-treated foot and mouth disease virus: comparison of two adjuvants in cattle[J]. Can J Comp Med, 1963, 27: 193-197.
56. Laport J, Grosclaude J, Wantyghem J, et al. Neutralization of the infective power of the foot-and-mouth disease virus in cell culture by using serums from pigs immunized with a purified viral protein[J]. C R Acad Sci Hebd Seances Acad Sci D, 1973, 276: 3399-401.
57. Bachrach HL, Moore DM, et al. Immune and antibody responses to an isolated capsid protein of foot-and-mouth disease virus[J]. J Immunol, 1975, 115(6): 1636-1641.
58. Meloen RH. Antibody response against foot and mouth disease virus (FMDV). Part I: Responses measured in sera of vaccinated steers with complete virus, trypsin treated virus, 12 S virus subunits and heterologous virus[J]. Zentralbl Veterinarmed B, 1979, 26: 273-83.
59. Kupper H, Keller W, Kurz CH, et al. Cloning of cDNA of major antigen of foot-and -mouth disease virus and expression in E.coli [J]. Nature, 1981, 289: 555-559.
60. Lewis SA, Morgan DO, Grubman MJ. Expression, processing, and assembly of foot-and-mouth disease virus capsid structures in heterologous systems: induction of a neutralizing antibody response in guinea pigs[J]. J Virol, 1991, 65: 6572-6580
61. Kield D G, Yansura D, Small B D, et al. Cloned viral protein vaccine for foot-and -mouth disease: responses in swine [J]. Sicence, 1981, 214:1125-1129.
62. Hobom G, Arnold N, Ruppert A. OmpA fusion proteins for presentation of foreign antigens on the bacterial outer membrane [J]. Dev Biol Stand, 1995, 84: 255-262.
63. Ratish G, Viswanathan S, Suryanarayana V V. C-terminal region of VP1 of selected foot-and-mouth disease virus serotypes: expression in E. coli and affinity purification [J]. Acta Virol, 1999, 43(4): 205-221.
64. Wang J H, Liang C M ,Peng J M,et al. Induction of immunity in swine bypurified recombinant VP1 of foot-and-mouth disease virus[J]. Vaccine, 2003, 21: 3721-3729.
65. Beesley KM, Francis MJ, Clarke BE, et al. Expression in yeast of amino-terminal peptide fusions to hepatitis B core antigen and their immunological properties[J]. Biotechnology, 1990, 8(7): 644-649.
66. Balamurugan V, Renji R, Saha SN, et al. Protective immune response of the capsid precursor polypeptide (P1) of foot and mouth disease virus type O produced in Pichia pastoris[J]. Virus Res, 2003, 92(2): 141-149.
67.冷青文,郭慧琛,刘在新,等.口蹄疫病毒P12X3C3D多基因编码蛋白在昆虫细胞中的表达与检测.中国兽医学报, 2006, 26: 229-231.
68.任林柱,王兴龙,崔丽瑾等.口蹄疫病毒WFL株ORF基因真核表达质粒的构建及病毒的拯救. 中国生物工程杂志,2008,28:27-31.
69. Kit S, Kit M, Dimarchi RD, et al. Modified-live infectious bovine rhinotracheitis virus vaccine expressing monomer and dimmer forms of foot-and-mouth disease capsid protein epitopes on surface of hybrid virus particles[J]. Arch Virol, 1991, 120: 1-17.
70. Abrams CC, King AM, Belsham GJ. Assembly of foot-and-mouth disease virus empty capsids synthesized by a vaccinia virus expression system[J]. J Gen Virol, 1995, 76(12): 3089-3098.
71. Grigera PR, Garcia-Briones M, Periolo O, et al. Immunogenicity of an aphthovirus chimera of the glycoprotein of vesicular stomatitis virus. J Virol, 1996, 70(12): 8492-8501.
72. Sanz-Parra A, Uazquez B, Sobrino F, et al. Evidence of partial protection against foot-and-mouth disease in cattle immunized with a recombinant adenovirus vector expressing the precursor poly peptide (P1) of foot-and-mouth disease virus capsid protein [J]. J Gen Virol, 1999, 80: 671-679.
73. Berinstein A, Tami C, Taboga O, et al. Protective immunity against foot-and-mouth disease virus induced by a recombinant vaccinia virus[J].Vaccine, 2000, 18: 2231-2238.
74. Mayr GA, O’Donnell V, Chinsangaram J, et al. Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs[J]. Vaccine, 2001, 19: 2152-2162.
75.王炜,张永光,潘丽,等.口蹄疫病毒P12A一3C免疫原基因在百脉根中的遗传转化与表达.中国人兽共患病学报,2007, 23:236-247.
76. Wigdorovitz A, Filgueora DM, Robertson N, et al. Protection of mice against challenge with foot-and-mouth disease virus (FMDV) by immunization with foliar extracts from plants infected with recombinant tobacco mosaic virus expressing the FMDV structural protein VP1[J]. Virology, 1999, 264: 85-91.
77. Carrillo C, Wigdorovitz A, Trono K, et al. Induction of a virus-specific antibodyresponse to foot and mouth disease virus using the structural protein VP1 expressed in transgenic potato plants[J]. Viral Immunol, 2001, 14(1): 49-57.
78. Wigdorovitz A, Carrillo C, Dus Santos MJ, et al. Induction of a protective antibody response to foot and mouth disease virus in mice following oral or parenteral immunization with alfalfa transgenic plants expressing the viral structural protein VP1[J]. Virology, 1999, 255(2): 347-353.
79. Dus Santos MJ, Wigdorovitz A, Trono K, et al. A novel methodology to develop a foot and mouth disease virus (FMDV) peptide-based vaccine in transgenic plants[J]. Vaccine, 2002, 20(7-8): 1141-1147.
80. Rowlands DJ, Sangar DV, Brown F. A comparative chemical and serological study of the full and empty particles of foot-and mouth disease virus[J]. The Journal of General Virology, 1975, 26(3): 227–38.
81. Rweyemamu MM, Terry G, Pay TW. Stability and immunogenicity of empty particles of foot-and-mouth disease virus[J]. Archives of Virology, 1979, 59(1–2): 69–79.
82. Roosien J, Belsham GJ, Ryan MD, King AM, Vlak JM. Synthesis of foot-and-mouth disease virus capsid proteins in insect cells using baculovirus expression vectors[J]. The Journal of General Virology, 1990, 71: 1703–11.
83. Abrams CC, King AM, Belsham GJ. Assembly of foot-and-mouth disease virus empty capsids synthesized by a vaccinia virus expression system[J]. The Journal of General Virology, 1995, 76: 3089–98.
84. Vakharia VN, Devaney MA, Moore DM, Dunn JJ, et al. Proteolytic processing of foot-and-mouth disease virus polyproteins expressed in a cell-free system from clone-derived transcripts[J]. Journal of Virology, 1987, 61(10): 3199–3207.
85. Grubman MJ, Lewis SA, Morgan DO. Protection of swine against foot-and-mouth disease with viral capsid proteins expressed in heterologous systems[J].Vaccine, 1993, 11(8): 825–829.
86. Saiz JC, Cairo J, Medina M, et al. Unpro-cessed foot-and-mouth disease virus capsid precursor displays discontinuous epitopes involved in viral neutralization[J]. Journal of Virology, 1994, 68(7): 4557–4564.
87. Chinsangaram J, Beard C, Mason PW, et al. Antibody response in mice inoculated with DNA expressing foot-and-mouth disease virus capsid proteins[J]. Journal of Virology, 1998, 72(5): 4454–4457.
88. Sanz-Parra A, Blasco R, Sobrino F, et al. Analysis of the B and T cell response in guinea pigs induced with recombinant vaccinia expressing foot-and-mouth disease virus structural proteins[J]. Archives of Virology, 1998, 143(2): 389–398.
89. Mayr GA, Chinsangaram J, Grubman MJ. Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate[J]. Virology, 1999, 263(2): 496–506.
90. Mayr GA, O’Donnell V, Chinsangaram J, et al. Immune responses and protection against foot-and-mouth disease virus (FMDV) hallenge in swine vaccinated with adenovirus-FMDV constructs[J]. Vaccine, 2001,19: 2152–2162
91. Moraes MP, Mayr GA, Mason PW, et al. Early protection against homol-ogous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24[J]. Vaccine, 2002, 20: 1631–1639.
92. Pacheco JM, Brum MC, Moraes MP, et al. Rapid protec-tion of cattle fromdirect challenge with foot-and-mouth disease virus (FMDV) by a single inoculation with an adenovirus-vectored FMDV subunit vaccine[J]. Virology, 2005, 337(2): 205–209.
93. Ma M, Jin N, Shen G, et al. Immune responses of swine inoculated with a recombinant fowlpox virus co-expressing P12A and 3C of FMDV and swine IL-18[J]. Veterinary Immunology and Immunopathology, 2008, 121: 1–7.
94. Mingxiao M, Ningyi J, Juan LH, et al. Immuno-genicity of plasmids encoding P12A and 3C of FMDV and swine IL-18[J]. Antiviral Research, 2007, 76(1): 59–67.
95. Li X, Liu R, Tang H, et al. Induction of protective immunity in swine by immunization with live attenuated recombinant pseudorabies virus expressing the capsid precursor encoding regions of foot-and-mouth disease virus[J]. Vaccine, 2008, 26(22): 2714–2722.
96. Li Z, Yi Y, Yin X, et al. Expression of foot-and-mouth disease virus capsid proteins in silkworm-baculovirus expression system and its utilization as a subunit vaccine[J]. PloS One, 2008, 3(5): e2273.
97. Pena L, Moraes MP, Koster M, et al. Delivery of a foot-and-mouth disease virus empty capsid subunit antigen with nonstructural protein 2B improves protection of swine[J].Vaccine, 2008 26: 5689–5699.
98. Cao Y, Lu Z, Sun P, et al. A pseudotype baculovirus expressing the capsid protein of foot-and-mouth disease virus and a T-Cell immunogen shows enhanced immunogenicity in mice[J]. Virology J, 2011, 8: 77-86.
99. Carrillo C, Wigdorovitz A, Oliveros J C,et al. Protective immune response to foot-and-mouth disease virus with VP1 expressed in transgenic plants[J]. J Virol,1998, 72(2): 1688-1690.
100.张娅,曾君祉,陈耀锋,等.口蹄疫病毒VP1基因在胡萝卜中的表达[J].西北农林科技大学学报(自然科学版)[J], 2007, 35: 75-80.
101.Beard C, Ward G, Rieder E, et al. Development of DNA vaccines for foot-and-mouth disease, evaluation of vaccines encoding replicating and non-replicating nucleic acids in swine[J]. J Biotechnol, 1999, 73: 243-249.
102.Fan H, Tong T, Chen H, et al. Immunization of DNA vaccine encoding C3d-VP1 fusion enhanced protective immune response against foot-and-mouth disease virus[J]. Virus Genes, 2007, 35: 347-357.
103.Choudary S, Ravikumar P, Ashok Kumar C, et al. Enhanced immune response of DNA vaccine (VP1-pCDNA) adsorbed on cationic PLG for foot and mouth disease in guinea pigs[J]. Virus Genes, 2008, 37: 81-87.
104. Wong HT, Cheng SC, Chan EW, et al. Plasmids encoding foot-and-mouth disease virus VP1 epitopes elicited immune responses in mice and swine and protected swine against viral infection[J]. Virology, 2000, 278: 27-35.
105. Wong HT, Cheng SC, Sin FW, et al. A DNA vaccine against foot-and-mouth disease elicits an immune response in swine which is enhanced by co-administration with interleukin-2[J]. Vaccine, 2002, 20: 2641-2647.
106. Jin H, Xiao W, Xiao C, et al. Protective immune responses against foot-and-mouth disease virus by vaccination with a DNA vaccine expressing virus-like particles[J]. Viral Immunol, 2007, 20: 429-440.
107. Wang F, He XW, Jiang L, et al. Enhanced immunogenicity of microencapsulated multiepitope DNA vaccine encoding T and B cell epitopes of foot-and-mouth disease virus in mice[J]. Vaccine, 2006, 24: 2017-2026.
108.Guo H, Liu Z, Sun S, et al. Immune response in guinea pigs vaccinated with DNA vaccine of foot-and-mouth disease virus O/China99[J]. Vaccine, 2005, 23: 3236-3242.
109.Broekhuijsen MP, van Rijn JM, Blom AJ, et al. Fusion proteins with multiple copies of the major antigenic determinant of foot-and-mouth disease virus protect both the natural host and laboratory animals[J]. J Gen Virol, 1987, 68: 3137-3143.
110.Broekhuijsen MP, Blom T, Van Rijn J, et al. Synthesis of fusion proteins with multiple copies of an antigenic determinant of foot-and-mouth disease virus[J]. Gene, 1986, 49 (2): 189-197.
111.Francis MJ, Fry CM, Rowlands DJ, et al. 1987. Immune response to uncoupled peptides of foot-and-mouth disease virus. Immunology 61:1-6.
112.Ferguson M, Evans DM, and Magrath DI, et al. Induction by synthetic peptides of broadly reactive, type-specific neutralizing antibody to poliovirus type 3 [J]. Virology, 1985, 143 (2): 505-515.
113.Dreesman R, Sanchez Y, and Ionescu-Matiu I, et al. Antibody response to hepatitis B surface antigen after a single inoculation of uncouple synthetic HBsAG peptides [J]. Nature, 1982, 295: 505-508.
114. Wang YS, Fan HJ, Li Y, et al. Development of a multi-mimotope peptide as a vaccine immunogen for infectious bursal disease virus [J]. Vaccine, 2007, 25 (22): 4447-4455.
115.Cai QL, Peng GY, Bu LY, et al. Immunogenicity and in vitro protective efficacy of a polyepitope plasmodium falciparum candidate accine construted by epitope shuffling [J]. Vaccine, 2007, 25: 5155-5165.
116.Hua B, Li C, Lu H, et al. Immune responses to the oral administration of recombinant Bacillus subtilis xpressing multi-epitopes of foot-and-mouth disease virus and a choleratoxin B subunit[J]. J Virol Methods, 2011, 171: 272–279.
117.Clarke BE, Newton SE, Carroll AR, et al. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein [J]. Nature, 1987, 330: 381-384.
118.Wu LG, Jiang LB, and Zhou ZA, et al. Expression of foot-and-mouth disease virus epitopes in tobacco by a tobacco mosaic virus-based vector [J]. Vaccine, 2003, 21: 4390-4398.
119.Jiang LB, Li QL, and Li MM, et al. A modified TMV-based vector facilitates the expression of longer foreign epitopes in tobacco [J]. Vaccine, 2006, 24: 109-115.
120.Chan EW, Wong HT, Cheng SC, et al. An immunoglobulin G based chimeric protein induced foot-and-mouth disease specific immune response in swine [J]. Vaccine, 2001, 19: 538-546.
121.Shao JJ, Wong CH, Chang H, et al. A promising multiple-epitope recombinant vaccine against foot-and-mouth disease virus type O in swine[J]. Clinical and vaccine immunology, 2011, 18: 143-149.
122.Du Y, Li Y, He H, et al. Enhanced immunogenicity of multiple epitopes of foot-and-mouth disease virus fused with porcine interferon-αin mice and protective efficacy in guinea pigs and swine[J]. Journal of Virology methods, 2008, 149: 144-152.
123. Li J, Li KW, Gao J, et al. Heat shock protein 70 fused to or complexed with hantavirus nucleocapsid protein significantly enhances specific humoral and cellular immune response in C57BL/6 mice[J]. Vaccine, 2008, 26: 3175-3187.
124.Brumeanu T D, Swiggard W J, Steinman R M, et al. Efficient loading of identicalviral peptide onto classⅡmolecules by antigenized immunoglobulin and influenza virus [J]. J Exp Med, 1993, 178 (5): 1795-1799.
125.Zaghouani H, Steinman R, and Nonacs R, et al. presentation of a viral T cell epitope expressed in the CDR3 region of a self immunogolobulin molecule [J]. Science, 1993, 259 (5092): 224-227.
126.Langeveld JPM, Kamstrup S, Uttenthal A. et al. Full protection in mink against mink enteritis virus with new generation canine parvovirus vaccines based on synthetic peptide or recombinant protein[J]. Vaccine, 1995, 13: 1033-1037.
127. Rieder E, Baxt B, Lubroth J, et al. Vaccines prepared from chimeras of foot-and-mouth disease virus (FMDV) induce neutralizing antibodies and protective immunity to multiple serotypes of FMDV[J]. J Virol, 1994, 68: 2092-2098.
128. Zamorano P, Wigdorovitz A, Perez-Filgueira M, et al. A 10-amino-acid linear sequence of VP1 of foot and mouth disease virus containing B- and T-cell epitopes induces protection in mice[J]. Virology, 1995, 212: 614-621.
129.Collen T, Pullen L, Doel TR. T cell-dependent induction of antibody against foot-and-mouth disease virus in a mouse model[J]. J Gen Virol, 1989, 70: 395-403.
130.Collen T, Dimarchi R, Doel TR. A T cell epitope in VP1 of foot-and-mouth disease virus is immunodominant for vaccinated cattle[J]. J Immunol, 1991, 146: 749-755.
131.Blanco E, Garcia-Briones M, Sanz-Parra A, et al. Identification of T-cell epitopes in nonstructural proteins of foot-and-mouth disease virus[J]. J Virol, 2001, 75: 3164-3174.
132.Van Lierop MJ, Nilsson PR, Wagenaar JP, et al. The influence of MHC polymorphism on the selection of T-cell determinants of FMDV in cattle[J]. Immunology, 1995, 84: 79-85.
133.Perez Filgueira, Wigdorovitz MA, Romera A, et al. Detection and characterization of functional T-cell epitopes on the structural proteins VP2, VP3, and VP4 of foot and mouth disease virus O1 campos[J]. Virology, 2000, 271:234-239.
134.Gerner W, Hammer SE, Wiesmuller KH, et al. Identification of major histocompatibility complex restriction and anchor residues of foot-and-mouth disease virus-derived bovine T-cell epitopes[J]. J Virol, 2009, 83: 4039-4050.
135. Gerner W, Carr BV, Wiesmuller KH, et al. Identification of a novel foot-and-mouth disease virus specific T-cell epitope with immunodominant characteristics in cattle with MHC serotype A31[J]. Vet Res, 2007, 38: 565-572.
136. Collen T, Baron J, Childerstone A, et al. Heterotypic recognition of recombinant FMDV proteins by bovine T-cells: the polymerase (P3Dpol) as an immunodominant T-cell immunogen[J]. Virus Res, 1998, 56: 125-133.
137.Cedillo-Barón L, Foster-Cuevas M, Belsham G, et al. Induction of a protective response in swine vaccinated with DNA encoding foot-and-mouth disease virus empty capsid proteins and the 3D RNA polymerase[J]. J Gen Virol, 2001, 82: 1713– 1724.
138.Garcia-Briones MM, Blanco E, Chiva C, et al. Immunogenicity and T cell recognition in swine of foot-and-mouth disease virus polymerase 3D[J]. Virology 2004, 322: 264-275.
139.Ilott MC, Salt JS, Gaskell RM, et al. Dexamethasone inhibits virus production and the secretory IgA response in oesophageal-pharyngeal fluid in cattle persistently infected with foot-and-mouth disease virus[J]. Epidemiol Infect, 1997, 118: 181-187.
140.Sanz-Parra A, Vazquez B, Sobrino F, et al. Evidence of partial protection against foot-and-mouth disease in cattle immunized with a recombinant adenovirus vector expressing the precursor polypeptide (P1) of foot-and-mouth disease virus capsid proteins[J]. J Gen Virol, 1999, 80: 671-679.
141.Sanz-Parra A, Jimenez-Clavero MA,. Garcia-Briones MM, et al. Recombinant viruses expressing the foot-and-mouth disease virus capsid precursor polypeptide (P1) induce cellular but not humoral antiviral immunity and partial protection in pigs[J]. Virology, 1999, 259: 129-134.
142.Guzman E, Taylor G, Charleston B, et al. An MHC-restricted CD8+ T-cellresponse is induced in cattle by foot-and-mouth disease virus (FMDV) infection and also following vaccination with inactivated FMDV[J]. J Gen Virol, 2008, 89: 667-675.
143.Armengol E, Wiesmuller KH, Wienhold D, et al. Identification of T-cell epitopes in the structural and non-structural proteins of classical swine fever virus[J]. J. Gen Virol, 2002, 83: 551–560.
144. Glass EJ, Millar P. Induction of effective cross-reactive immunity by FMDV peptides is critically dependent upon specific MHC-peptide-T cell interactions[J]. Immunology, 1994, 82: 1-8.
145.Shieh JJ, Liang CM, Chen CY, et al. Enhancement of the immunity to foot-and-mouth disease virus by DNA priming and protein boosting immunization[J].Vaccine, 2001, 19: 4002-4010.
146.Tam JP. Synthetic peptide vaccine design: Synthesis and properties of a high-density multiple antigenic peptide system[J]. Proc Natl Acad Sci, 1988, 85: 5409-5413.
147.Volpina OM, Yarov AV, Zhmak MN, et al. Synthetic vaccine against foot-and-mouth disease based on a palmitoyl derivative of the VP1 protein
135-159 fragment of the A22 virus strain[J]. Vaccine, 1996, 14: 1375-1380.
148.Francis MJ, Fry CM, Rowlands DJ, et al. Qualitative and quantitative differences in the immune response to foot-and-mouth disease virus antigens and synthetic peptides[J]. J Gen Virol, 1988, 69: 2483-2491.
149.Francis MJ, Hastings GZ, Brown F, et al. Immunological evaluation of the multiple antigen peptide (MAP) system using the major immunogenic site of foot-and-mouth disease virus[J]. Immunology, 1991, 73: 249-254.
150.Wang CY, Chang TY, Walfield AM, et al. Effective synthetic peptide vaccine for foot-and-mouth disease in swine[J]. Vaccine, 2002, 20: 2603-2610.
151.Sanchez J, Holmgren J. Cholera toxin-A foe & a friend[J]. Indian J Med Res, 2011, 133(2): 153-163.
152. O’Dowd M. Novel modification to c-terminus of LTB that facilitate side-directed chemical coupling of antigens and the development of LTB as acarrier for mucosal vaccines[J]. Vaccine, 1999, 17: 1442-1453.
153.Romeu B, González E, Del Campo J, et al. Mucosal and systemic immune responses of mice to tetanus toxoid coadministered nasally with AFCo1[J]. Can J Microbiol, 2011, 57(3): 256-261.
154.Edelman R. The development and use of vaccine adjuvants[J]. Mol Biotechnol 2002, 21: 129–148.
155.Xiao C, Jin H, Hu Y, Kang Y, et al. Enhanced protective efficacy and reduced viral load of foot-and-mouth disease DNA vaccine with co-stimulatory molecules as the molecular adjuvants[J]. Antiviral Res, 2007, 76: 11-20.
156.Cheng G, Zhao X, Yan W, et al. Alpha interferon is a powerful adjuvant for a recombinant protein vaccine against foot-and-mouth disease virus in swine, and an effective stimulus of in vivo immune response[J]. Vaccine, 2007, 25: 5199-5208.
157.Zhang X, He P, Hu Z, et al. Enhanced specific immune responses by CpG DNA in mice immunized with recombinant hepatitis B surface antigen and HB vaccine[J]. Virol J, 2011, 8: 78-84.
158.Devriendt B, De Geest BG, Cox E, et al. Designing oral vaccines targeting intestinal dendritic cells[J]. Expert Opin Drug Deliv, 2011, 8(4): 467-483.
159.Foldvari M. Biphasic vesicles: a novel topical drug delivery system[J]. J Biomed Nanotechnol, 2010, 6(5): 543-557.
160.Doel TR. Natural and vaccine induced immunity to FMD[J]. Curr Top Microbiol Immunol, 2005, 288: 103-131.
161.J.萨姆布鲁克,D.W.拉塞尔著,黄培堂等译.《分子克隆》实验指南(第三版)[M].科学出版社,北京,2003.
162.汪家政,范明主编.《蛋白质技术手册》[M].科学出版社,北京,2000.
163.世界动物卫生组织著,农业部兽医局/中国动物卫生与流行病学中心译《.陆生动物诊断试验和疫苗手册》(哺乳动物、禽鸟与蜜蜂).2007年.
2. Thomson GR, Vosloo W, Bastos AD. Foot and mouth disease in wildlife[J]. Virus Res, 2003, 91: 65-80.
3. Grubman MJ, Baxt B. Foot-and-mouth disease[J]. Clin Microbiol Rev, 2004, 17(2): 465-493.
4. Yang PC, Chu RM, Chung WB, et al. Epidemiological characteristics and financial costs of the 1997 foot-and-mouth disease epidemic in Taiwan [J]. Vet Rec, 1999, 145(25): 731-734.
5. Haydon DT, Kao RR, Kitching RP. The UK foot-and-mouth disease outbreak—the aftermath[J]. Nature review: microbiology, 2004, 2:674-681.
6. Barnett PV, Pullen L, Williams L, et al. 1996. International bank for foot-and-mouth disease vaccine: assessment of Montanide ISA 25 and ISA 206, two commercially available oil adjuvants[J]. Vaccine, 14: 1187–1198.
7. Barteling SJ, Vreeswijk J. Developments in foot-and-mouth disease[J]. Vaccine, 1991, 9: 75-88.
8. Doel TR. FMD vaccines[J]. Virus Res, 2003, 91(1): 81-99.
9. Lu Z Cao Y, Guo J, et al. Development and validation of a 3ABC indirect ELISA for differentiation of foot-and-mouth disease virus infected from vaccinated animals[J]. Vet Microbiol, 2007, 125: 157-169.
10. Mackay DK, Forsyth MA, Davies PR, et al. Differentiating infection from vaccination in foot-and-mouth disease using a panel of recombinant, non-structural proteins in ELISA[J]. Vaccine, 1998, 16: 446-459.
11. Sutmoller P, Casas Olascoaga R. The risks posed by the importation of animals vaccinated against foot and mouth disease and products derived from vaccinated animals: a review[J]. Rev Sci Tech, 2003, 22: 823-835
12. Beck E, and Strohmaier K. Subtyping of European foot-and-mouth disease virusstrains by nucleotide sequence determination[J]. J Virol, 1987, 61: 1621-1629.
13. Brown F. New approaches to vaccination against foot-and-mouth disease[J]. Vaccine, 1992, 10: 1022-1026.
14. King AM, Underwood BO, McCahon D, et al. Biochemical identification of viruses causing the 1981 outbreaks of foot and mouth disease in the UK[J]. Nature, 1981, 293: 479-480.
15. Wu Q, Moraes MP, Grubman M J. Recombinant adenovirus co-expressing capsid proteins of two serotypes of foot-and-mouth disease virus (FMDV): in vitro characterization and induction of neutralizing antibodies against FMDV in swine [J]. Virus Res, 2003, 93: 211-219.
16. Yi JZ, Liu MQ, Zhu CZ, et al. Recombinant bivalent vaccine against Foot-and-Mouth Disease Virus Serotype O/A infection in guinea pig[J]. Acta. Biochemica et Biophysica Sinica, 2004, 36: 589-596.
17. He YN, Qian P, Zhang KS, et al. Construction and immune response characterization of a recombinant pseudorabies virus co-expressing capsid precursor protein (P1) and a multiepitope peptide of foot-and-mouth diesase virus in swine[J]. Virus Genes, 2008, 36: 393-400.
18. Sanz-Parra A, Vázquez B, Sobrino F, et al. Evidence of partial protection against foot-and-mouth disease in cattle immunized with a recombinant adenovirus vector expressing the precursor polypeptide (P1) of foot-and-mouth disease virus capsid proteins[J]. J Gen Virol, 1999, 80: 671-679.
19. Sanz-Parra A, Jimenez-Clavero MA, García-Briones MM, et al. Recombinant viruses expressing the foot-and-mouth disease virus capsid precursor polypeptide (P1) induce cellular but not humoral antiviral immunity and partial protection in pigs[J]. Virology, 1999, 259: 129-134.
20. Lu Z, Bao H, Cao Y, et al. Protection of guinea pigs and swine by a recombinant adenovirus expressing O serotype of foot-and-mouth disease virus whole capsid and 3C protease[J]. Vaccine, 2008, 26S: G48–G53.
21. Bittle JL, Houghten RA, Alexander H, et al. Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted fromthe viral nucleotide sequence[J]. Nature, 1982, 298: 30-33.
22. Doel TR, Gale C, Do Amaral CM, et al. Heterotypic protection induced by synthetic peptides corresponding to three serotypes of foot-and-mouth disease virus[J]. J Virol, 1990, 64:2260-2264.
23. Meloen RH, Casal JI, Dalsgaard K, et al. Synthetic peptide vaccine: success at last[J]. Vaccine, 1995, 13: 127-133.
24. Morgan DO, Moore DM. Protection of cattle and swine against foot-and-mouth disease, using biosynthetic peptide vaccines[J]. Am J Vet Res, 1990, 51: 40-45.
25. Rodriguez LL, Barrera J, Kramer E, et al. A synthetic peptide containing the consensus sequence of the G-H loop region of foot-and-mouth disease virus type O VP1 and a promiscuous T-helper epitope induces eptide-specific antibodies but fails to protect cattle against viral challenge. Vaccine. 2003. 21: 3751-3756.
26. Su CX, Duan XG, Wang XQ, et al. Heterologous of FMDV immunodominant epitopes and HSP70 in P.pastoris and the subesequent immune response in mice[J]. Vet Mirobiol, 2007, 124: 256-263.
27. Winther MD, Allen G, Bomford RH, et al. Bacterially expressed antigenic peptide from foot-and-mouth disease virus capsid elicits variable immunologic responses in animals[J]. J Immunol, 1986, 136: 1835-1840.
28. Borrego B, Fernandez-Pacheco P, Ganges L, et al. Fernandez-Borges, F. Sobrino, and F. Rodríguez. DNA vaccines expressing B and T cell epitopes can protect mice from FMDV infection in the absence of specific humoral responses[J]. Vaccine. 2006, 24: 3889-3899.
29. Guo H, Sun S, Ma J, et al. A Bicistronic DNA Vaccine Containing Gene of FMDV and Bovine IFN-αCan Prime Humoral and Cellular Immune Responses of Guinea Pigs[J]. Turk J Vet Anim Sci, 2008, 32(2): 85-91.
30. Li Y, Stirling CMA, Michael S. Dramatic improvement in FMD DNA vaccine efficacy and cross-serotype antibody induction in pigs following a protein boost [J]. Vaccine, 2008, 26: 2647-2656.
31. Li Y, Aggarwal N, Takamatsu HH, et al. Enhancing immune responses against a plasmi DNA vaccine encoding a FMDV empty capsid from serotype O[J].Vaccine, 2006, 24: 4602-4606.
32. Yang B, Lan X, Li X, et al. A novel bi-functional DNA vaccine expressing VP1 protein and producing antisense RNA targeted to 5′UTR of foot-and-mouth disease virus can induce both rapid inhibitory effect and specific immune response in mice[J]. Vaccine, 2008, 26: 5477-5483.
33. Sutmoller P, Barteling SJ. The history of foot-and-mouth disease vaccine development: a personal perspective. In: foot-and-mouth disease: Control Strategies[M]. Dondet, B and Vicari, M. eds. Elsevier Amsterdam and New York. 337-343.
34. Sutmoller P, Barteling SS, Olascoaga RC, et al. Control and eradication of foot-and-mouth disease[J]. Virus Res, 2003, 91(1): 101-144.
35. Sa-Carvalho D, Rieder E, Baxt B, et al. Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle[J]. J Virol, 1997, 71: 5115–5123.
36. McKenna TS, Lubroth J, Rieder E, et al. Receptor binding site-deleted foot-and-mouth disease (FMD) virus protects cattle from FMD[J]. J Virol, 1995, 69: 5787–5790.
37. Brown CC, Piccone ME, Mason PW, et al. Pathogenesis of wild-type and leaderless foot-and-mouth disease virus in cattle[J]. J Virol, 1996, 70(8): 5638–5641.
38. Chinsangaram J, Mason PW, Grubman MJ. Protection of swine by live and inactivated vaccines prepared froma leader proteinase-deficient serotype A12 foot-and-mouth disease virus. Vaccine 1998;16(16):1516–1522.
39. Mason PW, Piccone ME, McKenna TS, et al. Evaluation of a live-attenuated foot-and-mouth disease virus as a vaccine candidate.Virology, 1997, 227(1): 96–102.
40. Almeida MR, Rieder E, Chinsangaram J, et al. Construction and evaluation of an attenuated vaccine for foot-and-mouth disease: difficulty adapting the leader proteinase-deleted strategy to the serotype O1 virus[J]. Virus Res, 1998, 55: 49–60.
41. Rodríguez Pulido M, Sobrino Francisco, Borrego B, et al. Attenuated Foot-and-Mouth Disease Virus RNA Carrying a Deletion in the 3′Noncoding Region Can Elicit Immunity in Swine[J]. J Virol, 2009, 38: 3475–3485.
42. Vallee H, Carre H, Rinjard P. On immunization agaisnt foot-and-mouth diesease [J]. Rech Med Vet, 1925, 101: 297-299.
43. Waldmann O, K?be K, Pyl G. Die aktive Immunisierung des Rindes gegen Maul-und Klauenseuche mittels Formolimpfstoff[J]. Zent Bakt Parasi Infekt, 1937, 138: 401-412.
44. Frenkel HS. La culture du virus de la fiévre aphteuse surl’épithélium de la langue des bovidés[J]. Bull, Off, Int, Epiz, 1947, 28: 155-162.
45. Francisico Sobrino, Esteban Domingo. Foot-and-mouth disease current perspectives[M]. British, 2004.
46. Ubertini B, Nardelli L, Dal Panina A, et al. BHK-21cell cultures for the large scale production of foot-and-mouth disease[J]. Zbl Vet Med B, 14: 432.
47. Capstick PB, Telling RC, Chapman WG, et al. Growth of a cloned strain of hamster kidney cells in suspended cultures and their susceptibility to the virus of foot-and-mouth disease[J]. Nature, 1962, 195: 1163-1164.
48. Telling RC, Elsworth R. Submerged culture of hamster kidney cells in a stainless steel vessel[J]. Biotechnol Bioeng, 1965, 7: 417-434.
49. Correa Melo E, Saraiva V, Astudillo V. Review of the status of foot and mouth disease in countries of South America and approaches to control and eradication[J]. Rev Sci Tech Off Int Epizoot, 2002, 21: 429–436.
50. Doel TR, Pullen L. International bank for foot-and-mouth disease vaccine: stability studies with virus concentrates and vaccines prepared from them[J]. Vaccine, 1990, 8: 473-478.
51. Brown F, Crick, Joan. Application of agar-gel diffusion analysis to a study of the antigenic structure of inactivated vaccines prepared from the virus of foot and mouth disease[J]. J Immunol, 1959, 82: 444-447.
52. Bahnemann HG. The inactivation of foot and mouth disease virus by ethyleneimine and propyleneimine[J]. Zbl Vet Med B, 1973, 20: 356-360.
53. Freund J. The mode of action of immunologic adjuvants[J]. Adv Tuberc Res, 1956, 7: 130-148.
54. Michelsen E. Experiences on vaccination of pigs[J]. Arch Exp Vet Med, 1961, 15: 317-321.
55. Cunliffe HR, Graves JH. Formalin-treated foot and mouth disease virus: comparison of two adjuvants in cattle[J]. Can J Comp Med, 1963, 27: 193-197.
56. Laport J, Grosclaude J, Wantyghem J, et al. Neutralization of the infective power of the foot-and-mouth disease virus in cell culture by using serums from pigs immunized with a purified viral protein[J]. C R Acad Sci Hebd Seances Acad Sci D, 1973, 276: 3399-401.
57. Bachrach HL, Moore DM, et al. Immune and antibody responses to an isolated capsid protein of foot-and-mouth disease virus[J]. J Immunol, 1975, 115(6): 1636-1641.
58. Meloen RH. Antibody response against foot and mouth disease virus (FMDV). Part I: Responses measured in sera of vaccinated steers with complete virus, trypsin treated virus, 12 S virus subunits and heterologous virus[J]. Zentralbl Veterinarmed B, 1979, 26: 273-83.
59. Kupper H, Keller W, Kurz CH, et al. Cloning of cDNA of major antigen of foot-and -mouth disease virus and expression in E.coli [J]. Nature, 1981, 289: 555-559.
60. Lewis SA, Morgan DO, Grubman MJ. Expression, processing, and assembly of foot-and-mouth disease virus capsid structures in heterologous systems: induction of a neutralizing antibody response in guinea pigs[J]. J Virol, 1991, 65: 6572-6580
61. Kield D G, Yansura D, Small B D, et al. Cloned viral protein vaccine for foot-and -mouth disease: responses in swine [J]. Sicence, 1981, 214:1125-1129.
62. Hobom G, Arnold N, Ruppert A. OmpA fusion proteins for presentation of foreign antigens on the bacterial outer membrane [J]. Dev Biol Stand, 1995, 84: 255-262.
63. Ratish G, Viswanathan S, Suryanarayana V V. C-terminal region of VP1 of selected foot-and-mouth disease virus serotypes: expression in E. coli and affinity purification [J]. Acta Virol, 1999, 43(4): 205-221.
64. Wang J H, Liang C M ,Peng J M,et al. Induction of immunity in swine bypurified recombinant VP1 of foot-and-mouth disease virus[J]. Vaccine, 2003, 21: 3721-3729.
65. Beesley KM, Francis MJ, Clarke BE, et al. Expression in yeast of amino-terminal peptide fusions to hepatitis B core antigen and their immunological properties[J]. Biotechnology, 1990, 8(7): 644-649.
66. Balamurugan V, Renji R, Saha SN, et al. Protective immune response of the capsid precursor polypeptide (P1) of foot and mouth disease virus type O produced in Pichia pastoris[J]. Virus Res, 2003, 92(2): 141-149.
67.冷青文,郭慧琛,刘在新,等.口蹄疫病毒P12X3C3D多基因编码蛋白在昆虫细胞中的表达与检测.中国兽医学报, 2006, 26: 229-231.
68.任林柱,王兴龙,崔丽瑾等.口蹄疫病毒WFL株ORF基因真核表达质粒的构建及病毒的拯救. 中国生物工程杂志,2008,28:27-31.
69. Kit S, Kit M, Dimarchi RD, et al. Modified-live infectious bovine rhinotracheitis virus vaccine expressing monomer and dimmer forms of foot-and-mouth disease capsid protein epitopes on surface of hybrid virus particles[J]. Arch Virol, 1991, 120: 1-17.
70. Abrams CC, King AM, Belsham GJ. Assembly of foot-and-mouth disease virus empty capsids synthesized by a vaccinia virus expression system[J]. J Gen Virol, 1995, 76(12): 3089-3098.
71. Grigera PR, Garcia-Briones M, Periolo O, et al. Immunogenicity of an aphthovirus chimera of the glycoprotein of vesicular stomatitis virus. J Virol, 1996, 70(12): 8492-8501.
72. Sanz-Parra A, Uazquez B, Sobrino F, et al. Evidence of partial protection against foot-and-mouth disease in cattle immunized with a recombinant adenovirus vector expressing the precursor poly peptide (P1) of foot-and-mouth disease virus capsid protein [J]. J Gen Virol, 1999, 80: 671-679.
73. Berinstein A, Tami C, Taboga O, et al. Protective immunity against foot-and-mouth disease virus induced by a recombinant vaccinia virus[J].Vaccine, 2000, 18: 2231-2238.
74. Mayr GA, O’Donnell V, Chinsangaram J, et al. Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs[J]. Vaccine, 2001, 19: 2152-2162.
75.王炜,张永光,潘丽,等.口蹄疫病毒P12A一3C免疫原基因在百脉根中的遗传转化与表达.中国人兽共患病学报,2007, 23:236-247.
76. Wigdorovitz A, Filgueora DM, Robertson N, et al. Protection of mice against challenge with foot-and-mouth disease virus (FMDV) by immunization with foliar extracts from plants infected with recombinant tobacco mosaic virus expressing the FMDV structural protein VP1[J]. Virology, 1999, 264: 85-91.
77. Carrillo C, Wigdorovitz A, Trono K, et al. Induction of a virus-specific antibodyresponse to foot and mouth disease virus using the structural protein VP1 expressed in transgenic potato plants[J]. Viral Immunol, 2001, 14(1): 49-57.
78. Wigdorovitz A, Carrillo C, Dus Santos MJ, et al. Induction of a protective antibody response to foot and mouth disease virus in mice following oral or parenteral immunization with alfalfa transgenic plants expressing the viral structural protein VP1[J]. Virology, 1999, 255(2): 347-353.
79. Dus Santos MJ, Wigdorovitz A, Trono K, et al. A novel methodology to develop a foot and mouth disease virus (FMDV) peptide-based vaccine in transgenic plants[J]. Vaccine, 2002, 20(7-8): 1141-1147.
80. Rowlands DJ, Sangar DV, Brown F. A comparative chemical and serological study of the full and empty particles of foot-and mouth disease virus[J]. The Journal of General Virology, 1975, 26(3): 227–38.
81. Rweyemamu MM, Terry G, Pay TW. Stability and immunogenicity of empty particles of foot-and-mouth disease virus[J]. Archives of Virology, 1979, 59(1–2): 69–79.
82. Roosien J, Belsham GJ, Ryan MD, King AM, Vlak JM. Synthesis of foot-and-mouth disease virus capsid proteins in insect cells using baculovirus expression vectors[J]. The Journal of General Virology, 1990, 71: 1703–11.
83. Abrams CC, King AM, Belsham GJ. Assembly of foot-and-mouth disease virus empty capsids synthesized by a vaccinia virus expression system[J]. The Journal of General Virology, 1995, 76: 3089–98.
84. Vakharia VN, Devaney MA, Moore DM, Dunn JJ, et al. Proteolytic processing of foot-and-mouth disease virus polyproteins expressed in a cell-free system from clone-derived transcripts[J]. Journal of Virology, 1987, 61(10): 3199–3207.
85. Grubman MJ, Lewis SA, Morgan DO. Protection of swine against foot-and-mouth disease with viral capsid proteins expressed in heterologous systems[J].Vaccine, 1993, 11(8): 825–829.
86. Saiz JC, Cairo J, Medina M, et al. Unpro-cessed foot-and-mouth disease virus capsid precursor displays discontinuous epitopes involved in viral neutralization[J]. Journal of Virology, 1994, 68(7): 4557–4564.
87. Chinsangaram J, Beard C, Mason PW, et al. Antibody response in mice inoculated with DNA expressing foot-and-mouth disease virus capsid proteins[J]. Journal of Virology, 1998, 72(5): 4454–4457.
88. Sanz-Parra A, Blasco R, Sobrino F, et al. Analysis of the B and T cell response in guinea pigs induced with recombinant vaccinia expressing foot-and-mouth disease virus structural proteins[J]. Archives of Virology, 1998, 143(2): 389–398.
89. Mayr GA, Chinsangaram J, Grubman MJ. Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate[J]. Virology, 1999, 263(2): 496–506.
90. Mayr GA, O’Donnell V, Chinsangaram J, et al. Immune responses and protection against foot-and-mouth disease virus (FMDV) hallenge in swine vaccinated with adenovirus-FMDV constructs[J]. Vaccine, 2001,19: 2152–2162
91. Moraes MP, Mayr GA, Mason PW, et al. Early protection against homol-ogous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24[J]. Vaccine, 2002, 20: 1631–1639.
92. Pacheco JM, Brum MC, Moraes MP, et al. Rapid protec-tion of cattle fromdirect challenge with foot-and-mouth disease virus (FMDV) by a single inoculation with an adenovirus-vectored FMDV subunit vaccine[J]. Virology, 2005, 337(2): 205–209.
93. Ma M, Jin N, Shen G, et al. Immune responses of swine inoculated with a recombinant fowlpox virus co-expressing P12A and 3C of FMDV and swine IL-18[J]. Veterinary Immunology and Immunopathology, 2008, 121: 1–7.
94. Mingxiao M, Ningyi J, Juan LH, et al. Immuno-genicity of plasmids encoding P12A and 3C of FMDV and swine IL-18[J]. Antiviral Research, 2007, 76(1): 59–67.
95. Li X, Liu R, Tang H, et al. Induction of protective immunity in swine by immunization with live attenuated recombinant pseudorabies virus expressing the capsid precursor encoding regions of foot-and-mouth disease virus[J]. Vaccine, 2008, 26(22): 2714–2722.
96. Li Z, Yi Y, Yin X, et al. Expression of foot-and-mouth disease virus capsid proteins in silkworm-baculovirus expression system and its utilization as a subunit vaccine[J]. PloS One, 2008, 3(5): e2273.
97. Pena L, Moraes MP, Koster M, et al. Delivery of a foot-and-mouth disease virus empty capsid subunit antigen with nonstructural protein 2B improves protection of swine[J].Vaccine, 2008 26: 5689–5699.
98. Cao Y, Lu Z, Sun P, et al. A pseudotype baculovirus expressing the capsid protein of foot-and-mouth disease virus and a T-Cell immunogen shows enhanced immunogenicity in mice[J]. Virology J, 2011, 8: 77-86.
99. Carrillo C, Wigdorovitz A, Oliveros J C,et al. Protective immune response to foot-and-mouth disease virus with VP1 expressed in transgenic plants[J]. J Virol,1998, 72(2): 1688-1690.
100.张娅,曾君祉,陈耀锋,等.口蹄疫病毒VP1基因在胡萝卜中的表达[J].西北农林科技大学学报(自然科学版)[J], 2007, 35: 75-80.
101.Beard C, Ward G, Rieder E, et al. Development of DNA vaccines for foot-and-mouth disease, evaluation of vaccines encoding replicating and non-replicating nucleic acids in swine[J]. J Biotechnol, 1999, 73: 243-249.
102.Fan H, Tong T, Chen H, et al. Immunization of DNA vaccine encoding C3d-VP1 fusion enhanced protective immune response against foot-and-mouth disease virus[J]. Virus Genes, 2007, 35: 347-357.
103.Choudary S, Ravikumar P, Ashok Kumar C, et al. Enhanced immune response of DNA vaccine (VP1-pCDNA) adsorbed on cationic PLG for foot and mouth disease in guinea pigs[J]. Virus Genes, 2008, 37: 81-87.
104. Wong HT, Cheng SC, Chan EW, et al. Plasmids encoding foot-and-mouth disease virus VP1 epitopes elicited immune responses in mice and swine and protected swine against viral infection[J]. Virology, 2000, 278: 27-35.
105. Wong HT, Cheng SC, Sin FW, et al. A DNA vaccine against foot-and-mouth disease elicits an immune response in swine which is enhanced by co-administration with interleukin-2[J]. Vaccine, 2002, 20: 2641-2647.
106. Jin H, Xiao W, Xiao C, et al. Protective immune responses against foot-and-mouth disease virus by vaccination with a DNA vaccine expressing virus-like particles[J]. Viral Immunol, 2007, 20: 429-440.
107. Wang F, He XW, Jiang L, et al. Enhanced immunogenicity of microencapsulated multiepitope DNA vaccine encoding T and B cell epitopes of foot-and-mouth disease virus in mice[J]. Vaccine, 2006, 24: 2017-2026.
108.Guo H, Liu Z, Sun S, et al. Immune response in guinea pigs vaccinated with DNA vaccine of foot-and-mouth disease virus O/China99[J]. Vaccine, 2005, 23: 3236-3242.
109.Broekhuijsen MP, van Rijn JM, Blom AJ, et al. Fusion proteins with multiple copies of the major antigenic determinant of foot-and-mouth disease virus protect both the natural host and laboratory animals[J]. J Gen Virol, 1987, 68: 3137-3143.
110.Broekhuijsen MP, Blom T, Van Rijn J, et al. Synthesis of fusion proteins with multiple copies of an antigenic determinant of foot-and-mouth disease virus[J]. Gene, 1986, 49 (2): 189-197.
111.Francis MJ, Fry CM, Rowlands DJ, et al. 1987. Immune response to uncoupled peptides of foot-and-mouth disease virus. Immunology 61:1-6.
112.Ferguson M, Evans DM, and Magrath DI, et al. Induction by synthetic peptides of broadly reactive, type-specific neutralizing antibody to poliovirus type 3 [J]. Virology, 1985, 143 (2): 505-515.
113.Dreesman R, Sanchez Y, and Ionescu-Matiu I, et al. Antibody response to hepatitis B surface antigen after a single inoculation of uncouple synthetic HBsAG peptides [J]. Nature, 1982, 295: 505-508.
114. Wang YS, Fan HJ, Li Y, et al. Development of a multi-mimotope peptide as a vaccine immunogen for infectious bursal disease virus [J]. Vaccine, 2007, 25 (22): 4447-4455.
115.Cai QL, Peng GY, Bu LY, et al. Immunogenicity and in vitro protective efficacy of a polyepitope plasmodium falciparum candidate accine construted by epitope shuffling [J]. Vaccine, 2007, 25: 5155-5165.
116.Hua B, Li C, Lu H, et al. Immune responses to the oral administration of recombinant Bacillus subtilis xpressing multi-epitopes of foot-and-mouth disease virus and a choleratoxin B subunit[J]. J Virol Methods, 2011, 171: 272–279.
117.Clarke BE, Newton SE, Carroll AR, et al. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein [J]. Nature, 1987, 330: 381-384.
118.Wu LG, Jiang LB, and Zhou ZA, et al. Expression of foot-and-mouth disease virus epitopes in tobacco by a tobacco mosaic virus-based vector [J]. Vaccine, 2003, 21: 4390-4398.
119.Jiang LB, Li QL, and Li MM, et al. A modified TMV-based vector facilitates the expression of longer foreign epitopes in tobacco [J]. Vaccine, 2006, 24: 109-115.
120.Chan EW, Wong HT, Cheng SC, et al. An immunoglobulin G based chimeric protein induced foot-and-mouth disease specific immune response in swine [J]. Vaccine, 2001, 19: 538-546.
121.Shao JJ, Wong CH, Chang H, et al. A promising multiple-epitope recombinant vaccine against foot-and-mouth disease virus type O in swine[J]. Clinical and vaccine immunology, 2011, 18: 143-149.
122.Du Y, Li Y, He H, et al. Enhanced immunogenicity of multiple epitopes of foot-and-mouth disease virus fused with porcine interferon-αin mice and protective efficacy in guinea pigs and swine[J]. Journal of Virology methods, 2008, 149: 144-152.
123. Li J, Li KW, Gao J, et al. Heat shock protein 70 fused to or complexed with hantavirus nucleocapsid protein significantly enhances specific humoral and cellular immune response in C57BL/6 mice[J]. Vaccine, 2008, 26: 3175-3187.
124.Brumeanu T D, Swiggard W J, Steinman R M, et al. Efficient loading of identicalviral peptide onto classⅡmolecules by antigenized immunoglobulin and influenza virus [J]. J Exp Med, 1993, 178 (5): 1795-1799.
125.Zaghouani H, Steinman R, and Nonacs R, et al. presentation of a viral T cell epitope expressed in the CDR3 region of a self immunogolobulin molecule [J]. Science, 1993, 259 (5092): 224-227.
126.Langeveld JPM, Kamstrup S, Uttenthal A. et al. Full protection in mink against mink enteritis virus with new generation canine parvovirus vaccines based on synthetic peptide or recombinant protein[J]. Vaccine, 1995, 13: 1033-1037.
127. Rieder E, Baxt B, Lubroth J, et al. Vaccines prepared from chimeras of foot-and-mouth disease virus (FMDV) induce neutralizing antibodies and protective immunity to multiple serotypes of FMDV[J]. J Virol, 1994, 68: 2092-2098.
128. Zamorano P, Wigdorovitz A, Perez-Filgueira M, et al. A 10-amino-acid linear sequence of VP1 of foot and mouth disease virus containing B- and T-cell epitopes induces protection in mice[J]. Virology, 1995, 212: 614-621.
129.Collen T, Pullen L, Doel TR. T cell-dependent induction of antibody against foot-and-mouth disease virus in a mouse model[J]. J Gen Virol, 1989, 70: 395-403.
130.Collen T, Dimarchi R, Doel TR. A T cell epitope in VP1 of foot-and-mouth disease virus is immunodominant for vaccinated cattle[J]. J Immunol, 1991, 146: 749-755.
131.Blanco E, Garcia-Briones M, Sanz-Parra A, et al. Identification of T-cell epitopes in nonstructural proteins of foot-and-mouth disease virus[J]. J Virol, 2001, 75: 3164-3174.
132.Van Lierop MJ, Nilsson PR, Wagenaar JP, et al. The influence of MHC polymorphism on the selection of T-cell determinants of FMDV in cattle[J]. Immunology, 1995, 84: 79-85.
133.Perez Filgueira, Wigdorovitz MA, Romera A, et al. Detection and characterization of functional T-cell epitopes on the structural proteins VP2, VP3, and VP4 of foot and mouth disease virus O1 campos[J]. Virology, 2000, 271:234-239.
134.Gerner W, Hammer SE, Wiesmuller KH, et al. Identification of major histocompatibility complex restriction and anchor residues of foot-and-mouth disease virus-derived bovine T-cell epitopes[J]. J Virol, 2009, 83: 4039-4050.
135. Gerner W, Carr BV, Wiesmuller KH, et al. Identification of a novel foot-and-mouth disease virus specific T-cell epitope with immunodominant characteristics in cattle with MHC serotype A31[J]. Vet Res, 2007, 38: 565-572.
136. Collen T, Baron J, Childerstone A, et al. Heterotypic recognition of recombinant FMDV proteins by bovine T-cells: the polymerase (P3Dpol) as an immunodominant T-cell immunogen[J]. Virus Res, 1998, 56: 125-133.
137.Cedillo-Barón L, Foster-Cuevas M, Belsham G, et al. Induction of a protective response in swine vaccinated with DNA encoding foot-and-mouth disease virus empty capsid proteins and the 3D RNA polymerase[J]. J Gen Virol, 2001, 82: 1713– 1724.
138.Garcia-Briones MM, Blanco E, Chiva C, et al. Immunogenicity and T cell recognition in swine of foot-and-mouth disease virus polymerase 3D[J]. Virology 2004, 322: 264-275.
139.Ilott MC, Salt JS, Gaskell RM, et al. Dexamethasone inhibits virus production and the secretory IgA response in oesophageal-pharyngeal fluid in cattle persistently infected with foot-and-mouth disease virus[J]. Epidemiol Infect, 1997, 118: 181-187.
140.Sanz-Parra A, Vazquez B, Sobrino F, et al. Evidence of partial protection against foot-and-mouth disease in cattle immunized with a recombinant adenovirus vector expressing the precursor polypeptide (P1) of foot-and-mouth disease virus capsid proteins[J]. J Gen Virol, 1999, 80: 671-679.
141.Sanz-Parra A, Jimenez-Clavero MA,. Garcia-Briones MM, et al. Recombinant viruses expressing the foot-and-mouth disease virus capsid precursor polypeptide (P1) induce cellular but not humoral antiviral immunity and partial protection in pigs[J]. Virology, 1999, 259: 129-134.
142.Guzman E, Taylor G, Charleston B, et al. An MHC-restricted CD8+ T-cellresponse is induced in cattle by foot-and-mouth disease virus (FMDV) infection and also following vaccination with inactivated FMDV[J]. J Gen Virol, 2008, 89: 667-675.
143.Armengol E, Wiesmuller KH, Wienhold D, et al. Identification of T-cell epitopes in the structural and non-structural proteins of classical swine fever virus[J]. J. Gen Virol, 2002, 83: 551–560.
144. Glass EJ, Millar P. Induction of effective cross-reactive immunity by FMDV peptides is critically dependent upon specific MHC-peptide-T cell interactions[J]. Immunology, 1994, 82: 1-8.
145.Shieh JJ, Liang CM, Chen CY, et al. Enhancement of the immunity to foot-and-mouth disease virus by DNA priming and protein boosting immunization[J].Vaccine, 2001, 19: 4002-4010.
146.Tam JP. Synthetic peptide vaccine design: Synthesis and properties of a high-density multiple antigenic peptide system[J]. Proc Natl Acad Sci, 1988, 85: 5409-5413.
147.Volpina OM, Yarov AV, Zhmak MN, et al. Synthetic vaccine against foot-and-mouth disease based on a palmitoyl derivative of the VP1 protein
135-159 fragment of the A22 virus strain[J]. Vaccine, 1996, 14: 1375-1380.
148.Francis MJ, Fry CM, Rowlands DJ, et al. Qualitative and quantitative differences in the immune response to foot-and-mouth disease virus antigens and synthetic peptides[J]. J Gen Virol, 1988, 69: 2483-2491.
149.Francis MJ, Hastings GZ, Brown F, et al. Immunological evaluation of the multiple antigen peptide (MAP) system using the major immunogenic site of foot-and-mouth disease virus[J]. Immunology, 1991, 73: 249-254.
150.Wang CY, Chang TY, Walfield AM, et al. Effective synthetic peptide vaccine for foot-and-mouth disease in swine[J]. Vaccine, 2002, 20: 2603-2610.
151.Sanchez J, Holmgren J. Cholera toxin-A foe & a friend[J]. Indian J Med Res, 2011, 133(2): 153-163.
152. O’Dowd M. Novel modification to c-terminus of LTB that facilitate side-directed chemical coupling of antigens and the development of LTB as acarrier for mucosal vaccines[J]. Vaccine, 1999, 17: 1442-1453.
153.Romeu B, González E, Del Campo J, et al. Mucosal and systemic immune responses of mice to tetanus toxoid coadministered nasally with AFCo1[J]. Can J Microbiol, 2011, 57(3): 256-261.
154.Edelman R. The development and use of vaccine adjuvants[J]. Mol Biotechnol 2002, 21: 129–148.
155.Xiao C, Jin H, Hu Y, Kang Y, et al. Enhanced protective efficacy and reduced viral load of foot-and-mouth disease DNA vaccine with co-stimulatory molecules as the molecular adjuvants[J]. Antiviral Res, 2007, 76: 11-20.
156.Cheng G, Zhao X, Yan W, et al. Alpha interferon is a powerful adjuvant for a recombinant protein vaccine against foot-and-mouth disease virus in swine, and an effective stimulus of in vivo immune response[J]. Vaccine, 2007, 25: 5199-5208.
157.Zhang X, He P, Hu Z, et al. Enhanced specific immune responses by CpG DNA in mice immunized with recombinant hepatitis B surface antigen and HB vaccine[J]. Virol J, 2011, 8: 78-84.
158.Devriendt B, De Geest BG, Cox E, et al. Designing oral vaccines targeting intestinal dendritic cells[J]. Expert Opin Drug Deliv, 2011, 8(4): 467-483.
159.Foldvari M. Biphasic vesicles: a novel topical drug delivery system[J]. J Biomed Nanotechnol, 2010, 6(5): 543-557.
160.Doel TR. Natural and vaccine induced immunity to FMD[J]. Curr Top Microbiol Immunol, 2005, 288: 103-131.
161.J.萨姆布鲁克,D.W.拉塞尔著,黄培堂等译.《分子克隆》实验指南(第三版)[M].科学出版社,北京,2003.
162.汪家政,范明主编.《蛋白质技术手册》[M].科学出版社,北京,2000.
163.世界动物卫生组织著,农业部兽医局/中国动物卫生与流行病学中心译《.陆生动物诊断试验和疫苗手册》(哺乳动物、禽鸟与蜜蜂).2007年.